Published in Gene Therapy Weekly, January 27th, 1997
B-cell CLL is the most common adult leukemia, and despite recent therapeutic advances, is still not considered curable. There are many reasons why CLL should be amenable to gene therapy, however, it is a leukemia of 'resting' B cells, and therefore not easily infected by retroviruses. This disease also has been shown to be resistant to most other currently available gene transfer techniques (e.g., electroporation, lipofectin, or amphotropic retrovirus infection).
In light of the potential role of gene transfer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.